What is ENLV's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.00B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ENLV?

P/E (TTM) is 0.00 and 52-week range is $0.20 to $27.15 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ENLV figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ENLV?

The company profile lists net income (TTM) near $2.52B, EPS (TTM) near $149.75 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Enlivex Ltd based, and what identifiers does Chartloom list?

The company context section lists headquarters in Ness Ziona, Central(HaMerkaz), IL, 16.8M shares outstanding, ISIN IL0011319527 when available from company profile and filing metadata.

Free AI scores & summaries library

Enlivex Ltd

$ENLV

Health Care · Biotechnology

IR Run Scenarios

$0.20

-0.54%

Free AI scores & summaries library

Enlivex Ltd

$ENLV

Health Care · Biotechnology

IR Run Scenarios

$0.20

-0.54%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Enlivex Ltd. engages in the development of macrophage reprogramming immunotherapy products. The company is headquartered in Ness Ziona, Central(Hamerkaz) and currently employs 34 full-time employees. The company went IPO on 2014-07-30. The firm focuses on diseases in which macrophages are pathologically reprogrammed, such as solid cancers, sepsis and COVID‑19, where non-homeostatic macrophages contribute significantly to disease severity. By re-establishing macrophage homeostasis, Allocetra has the potential to provide an immunotherapeutic mechanism of action for life-threatening indications defined as unmet medical needs, either as a stand‑alone therapy or in combination with other treatments.

Employees

34

Website

www.enlivex.com/

IPO

2014-07-30

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (TTM)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

IL0011319527

Headquarters

Ness Ziona, Central(HaMerkaz), IL

Shares outstanding

16.8M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

1.62%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Enlivex Ltd. engages in the development of macrophage reprogramming immunotherapy products. The company is headquartered in Ness Ziona, Central(Hamerkaz) and currently employs 34 full-time employees. The company went IPO on 2014-07-30. The firm focuses on diseases in which macrophages are pathologically reprogrammed, such as solid cancers, sepsis and COVID‑19, where non-homeostatic macrophages contribute significantly to disease severity. By re-establishing macrophage homeostasis, Allocetra has the potential to provide an immunotherapeutic mechanism of action for life-threatening indications defined as unmet medical needs, either as a stand‑alone therapy or in combination with other treatments.

Employees

34

Website

www.enlivex.com/

IPO

2014-07-30

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)